Company continues to focus on expanding its reach and organic growth, expense control, and laying foundation for advancing leadership position in genetic testing and precision medicine SALT LAKE CITY, ...

Paul J. Diaz, President and Chief Executive Officer: “In the midst of the COVID-19 pandemic, we continued to support our patients and healthcare providers with critical genetic insights needed to ...

In a report released on August 7, Puneet Souda from Leerink Partners maintained a Buy rating on Myriad Genetics (MYGN – Research Report), with a price target of $35.00. Puneet Souda has given his Buy ...

SALT LAKE CITY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the substantial completion of its strategic ...

B, as a powerful regulator that enhances wheat’s regeneration efficiency by balancing cytokinin levels and activating regeneration-related genes.